SLU-PP-332 closes the library. It is sold in the research-compound market
alongside metabolic peptides, so it belongs here — but it is important to be
clear about what it is.
Chemical identity & structure.
SLU-PP-332 is a small molecule, not a peptide. It is a synthetic compound
that acts on a class of nuclear receptors. It is included in this library only
because the research-compound market sells it in the "exercise-mimetic" /
metabolic category; it has no structural relationship to the peptides here.
Mechanism of action.
SLU-PP-332 is described as an agonist of the estrogen-related receptors (ERRs) —
nuclear receptors involved in regulating mitochondrial biogenesis and oxidative
metabolism, the same kinds of pathways that are upregulated by endurance
exercise. The research framing is that activating ERRs pharmacologically could
reproduce some of the metabolic adaptations of exercise — hence the
"exercise-mimetic" label. That label is a research concept, not an established
human effect.
Key research findings.
Preclinical research — in mice and cell models — has reported effects on
metabolism, oxidative-capacity markers, and exercise-related endpoints when ERRs
are pharmacologically activated. These preclinical findings are what generated
attention.
The research / citation base.
SLU-PP-332's evidence is preclinical only. There is no meaningful human
clinical data, and it is not approved for any use. Its human safety and
efficacy profile is entirely unknown. Marketing that presents it as a working
"exercise in a bottle" is far ahead of an evidence base that does not include
humans.
Administration.
No human clinical trial has established administration parameters for SLU-PP-332; VialTalk does not provide community-sourced dosing.
Quality & sourcing notes.
As a small molecule, identity and purity should be documented on a
batch-specific COA using small-molecule-appropriate methods (not peptide mass
spectrometry).
*Research-use note: Educational summary of published research. SLU-PP-332 is a
non-approved investigational compound with no human data; this is research
context only and not medical advice.*